PA.Sig: A Cell Death Program-Based Prognostic Signature for Glioma

A transcriptomic and clinical dataset from TCGA-GBMLGG and external cohorts used to develop a pyroptosis-apoptosis-associated gene signature (PA.Sig) for glioma. The signature stratifies patients into high- and low-risk groups with significantly different overall survival. It was created by Huaichao Zhang and published on figshare under a CC-BY-4.0 license.

Use Cases

• Prognostic risk stratification based on a cell death-associated gene signature.
• Analysis of tumor immune microenvironment characteristics linked to inflammatory cell death.
• Investigation of malignant cell state plasticity and intercellular communication patterns.
• Validation of therapeutic vulnerabilities associated with specific cell death landscapes.

Strengths

• Integrates transcriptomic and clinical data from TCGA-GBMLGG and external validation cohorts.
• Signature was validated through functional experiments in glioma cell lines treated with chemotherapeutic agents.
• Analyses include single-cell RNA sequencing data to delineate malignant cell states.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary data file is a 158.0 KB PDF, suggesting the dataset is a summary or supplementary material rather than raw data.

Provenance

Source

TCGA-GBMLGG and external validation cohorts.

Collection Method

Transcriptomic and clinical data analysis, integrative survival modeling, single-cell RNA sequencing analysis, and in vitro functional validation.

Freshness

Last updated 2026-05-21 04:39:04; freshness should be verified.